Co-chaperone p23 is a component of the heat-shock protein (Hsp)90 multiprotein-complex and is an important modulator of Hsp90 activity. Hsp90 client proteins involved in oncogenic survival signaling are frequently mutated in leukemia, and the integrity of the Hsp90 complex could therefore be important for leukemic cell survival. We demonstrate here that p23 is cleaved to a stable 17 kDa fragment in leukemic cell lines treated with commonly used chemotherapeutic drugs. The cleavage of p23 paralleled the activation of procaspase-7 and -3 and was suppressed by the caspase-3/-7 inhibitor DEVD-FMK. In vitro translated 35 S-p23 (in reticulocyte lysate) was cleaved at D142 and D145 by caspase-7 and -3. Cleavage of p23 occurred in caspase-3-deficient MCF-7 cells, suggesting a role for caspase-7 in intact cells. The Hsp90 inhibitor geldanamycin enhanced caspase-dependent p23 cleavage both in vitro and in intact cells. Geldanamycin also enhanced anthracycline-induced caspase activation and apoptosis. We conclude that p23 is a prominent target in leukemic cell apoptosis. Geldanamycin enhanced p23 cleavage both by rendering p23 more susceptible to caspases and by enhancing chemotherapy-induced caspase activation. These findings underscore the importance of the Hsp90-complex in antileukemic treatment, and suggest that p23 may have a role in survival signaling.
Introduction
Acute myelogenous leukemia (AML) remains the most common form of leukemia in the adult and elderly population. Currently, anthracyclines, cytarabine and etoposide are widely used in the treatment of AML due to their ability to induce apoptosis in leukemic cells. 1, 2 The signaling pathways by which these drugs work are not completely understood, but direct effects as DNA damage, mitochondrial electron transport interference, generation of oxidizing radicals and proteasomal activation have been demonstrated or hypothesized. 3, 4 In order to shed light on the molecular effects of anthracyclines and possibly identify potential targets for improved therapy, we searched by twodimensional gel electrophoresis (2DE) for protein modifications in the early phase of anthracycline-induced apoptosis.
We report here the proteolysis of heat-shock protein (Hsp)90 co-chaperone p23 in leukemic cell lines undergoing anthracycline-induced apoptosis. Hsp90 has recently got attention for its potential as a target in cancer therapy. 5 The benzoquinone ansamycin geldanamycin (GA), which displaces ATP from the amino-terminal ATP-binding site of Hsp90, 6 has been shown to interact preferentially with Hsp90 in cancer cells. 7 The 17-allylamino-17-demethoxygeldanamycin (17-AAG) derivative of GA is currently in clinical trial in cancer. 8 Under normal conditions, Hsp90 acts on a wide range of client proteins and is essential for conformational maturation of numerous oncogenic signaling proteins, including protein kinases and ligand-regulated transcription factors. 9, 10 Hsp90 acts in a multiprotein complex with several co-chaperones. 10 One of these, cochaperone p23, appears to stabilize Hsp90-complexes with steroid receptors 11 and oncogenic tyrosine kinases. 10, 12 p23 also has chaperone activity on its own and is able to inhibit aggregation of denatured proteins in the absence of ATP. 13, 14 The ATP antagonist GA blocks p23 association with Hsp90, 15 induces proteasomal degradation of survival signaling Hsp90 client proteins, 16, 17 activates the apoptosis-associated doublestranded RNA-dependent protein kinase, PKR, 18 and promotes an apoptotic rather than a necrotic death type. 19 p23 has increased expression in mammary carcinomas. 20 In the present study, we found that anthracyclines and other chemotherapeutic drugs like cytarabine and etoposide, but not GA alone, induced caspase-dependent cleavage of p23. The cleavage could be catalyzed by either caspase-7 or caspase-3 and occurred at D142 or D145 in the C-terminal tail of p23 that is believed to be required for chaperone activity. 21 The Hsp90 inhibitor GA was found to enhance caspase activation, p23 cleavage and apoptosis induced by anthracyclines. We conclude that Hsp90, and consequently signaling mediated by client proteins in the Hsp90 multiprotein complex, may be targeted through p23 in chemotherapy-induced cell death in AML.
Materials and methods

Cell culturing and assessment of apoptosis
The HL-60 cell line was obtained from ATCC (www.atcc.org), and the NB4 cell line was a generous gift from Dr M Lanotte (INSERM U-496, Centre G Hayem, Hospital St Louis, Paris, France). Cells were maintained in RPMI 1640 medium (Gibco, Grant Island, NY, USA) under standard conditions with 10% heat-inactivated fetal bovine serum (Gibco), L-glutamine (2 mM), streptomycin (5 mg/ml) and penicillin (5 U/ml). Cells were kept in logarithmic growth, and as a standard procedure cell density was adjusted to 0.4 Â 10 6 cells/ml before addition of drugs. The MCF-7 cell line was obtained from ATCC and was maintained in Dulbecco's modified Eagles's medium (DMEM, Invitrogen) with 10% heat-inactivated fetal bovine serum under standard conditions. Cells were grown to 60% confluence before addition of drugs. Daunorubicin (DNR), idarubicin (IDA), doxorubicin (DOXO), etoposide, cytarabine and geldanamycin were from Sigma-Aldrich Inc. (St Louis, MO, USA). The caspase inhibitors z-VAD(OMe)-FMK and z-DEVD(OMe)-FMK were from Alexis Corp. (Lausen, Switzerland) and recombinant caspase-3 and -7 were from Chemicon Int. (Temecula, CA, USA). Drugs were supplemented in the combinations and concentrations indicated in the text and figure legends.
After drug treatment, cells were fixed in phosphate-buffered saline containing 2% formaldehyde and screened for apoptosis using differential interference contrast microscopy to visualize surface membrane budding and chromatin condensation. Three different fields were randomly selected for the counting of at least 300 cells. All experiments were repeated at least three times. Percent apoptosis is defined as the ratio between cells with membrane budding/chromatin condensation and the total number of cells counted. Significant differences between values obtained for a population of cells treated with different experimental conditions were determined by means of the nonparametric Wilcoxon signed-rank test.
For 2DE and immunoprecipitation, cells were labeled with 35 S-methionine (SJ1515, Amersham Biosciences, Uppsala, Sweden). Cells were resolved in methionine-free RPMI (0.75 Â 10 6 cells/ml) and labeled with 0.20 mCi/ml for 1.5 h. After labeling, cells were washed twice in RPMI with methionine and left for 0.5 h to re-equilibrate before treatment with drugs.
Two-dimensional gel electrophoresis (2DE)
Reagents and materials for 2DE, including IPG-strips pH 3-10, were from Amersham Biosciences (Uppsala, Sweden).
Samples (in triplicate) were routinely from 20 million cells. Cells were washed twice in 0.9% NaCl and precipitated in 7% trichloroacetic acid (TCA). After centrifugation (14 000 Â g, 20 min), the pellet was washed once in 1 ml 5% TCA, twice in water-saturated diethylether, and briefly air-dried. The pellet was dissolved in 0.3 ml 2DE sample buffer (8.45 M urea, 5 mM Tris, 2% CHAPS, 100 mM dithioerythritol (DTE), 50 mM brom phenol blue), and stored at À801C. 3-10 ampholyte (final 2.5%) was added to the sample before isoelectric focusing.
Protein separation by first dimension (isoelectric focusing) was performed using 18 or 24 cm IPG-strips, pH range 3-10. Strips were hydrated for 18 h in 8 M urea, 20 mM DTE, 2.5% ampholyte, 1% w/v CHAPS and brom phenol blue. The ampholyte composition for IPG-strips pH 3-10 was Pharmalyte pH 3-10 (2%) and Pharmalyte pH 5-6 (0.5%). The sample (0.1 ml) was loaded in cups placed at the anodic side of the strips. The IPG-strips were run for 3 h in a 1-60 V gradient, 6 h 60-300 V, 6 h 300-3500 V, and 18-28 h 3500 V. After completion of focusing, the IPG-strips were equilibrated for 15 min in 28 mM Tris pH 8.45, 1.3% sodium dodecyl sulfate (SDS), 6.5 M urea, 26% glycerol and 100 mM DTE, and for another 15 min in the same buffer with 24 mM iodoacetamide replacing DTE.
The second dimension tricine-SDS-PAGE 22 was with 13.5% acrylamide separation gel and 4% acrylamide stacking gel. Gels with 35 S-methionine-labeled proteins were dried and subjected to phosphoimaging analysis on a Fuji BAS5000. For mass spectrometry analysis, gels were stained with Sypro Ruby and imaged in a Fuji LAS1000 before spots were manually picked.
Matrix-assisted laser desorption ionization-time-offlight-mass spectroscopy (MALDI-TOF-MS) protein identification
Proteins excised from gels were in-gel digested overnight with sequence-grade trypsin (Promega, Madison, WI, USA) in a total volume of 100 ml. Peptide samples were concentrated and desalted using Poros 50 R2 beads (Applied Biosystems, Foster City, CA, USA). Peptides concentrated on the chromatographic beads were eluted in a small volume of matrix solution and transferred to the MALDI-target for analysis on a Bruker Reflex III MALDI-TOF mass spectrometer (Bruker Daltonik, Bremen, Germany). Mass spectra were recorded in a positive reflector mode. The Mascot algorithm (available at www.matrixscience. com) was used for protein identification from the obtained peptide mass fingerprints.
Western blot analysis
Cells were washed in phosphate-buffered saline before lysis in 10 mM K 2 HPO 4 , 10 mM KH 2 PO 4 , 1 mM EDTA (pH 6.8) containing 10 mM CHAPS, 50 mM NaF, 0.3 mM NaVO 3 and Complete mini protease inhibitor (Roche Molecular Biochemicals). Lysates were homogenized with a mini-piston for 3 Â 5 s on ice and then centrifuged (10 000 Â g, 20 min, 41C Immunoprecipitation HL-60 cells were treated with vehicle or DNR and prepared as described under Western blot analysis. Extracts were incubated with anti-p23 and colloidal superparamagnetic mMACS Protein G MicroBeads (Miltenyi Biotec, Auburn, CA, USA) according to the protocol provided. The magnetically labeled immunecomplex was bound to a m-Column (Miltenyi Biotec) placed in a magnetic field and subsequently eluted from the column with 50 mM Tris pH 6.8, 10% glycerol, 2% SDS, 100 mM dithiothreitol (DTT) and 0.05% brom phenol blue (1 Â SDS-sample buffer). For 2DE analyses, cells were labeled with 35 Smethionine before drug treatment and the eluted immune complex was diluted 1:1 in 2DE sample buffer. 2DE was then performed as described and gels were subjected to phosphoimaging analysis.
p23 constructs and mutagenesis p23 cDNA (GenBank #L24804 subcloned into pGEM7Z) was generously supplied by Dr David O. Toft. p23 was subcloned into a strep-tagged pcDNA5/FRT expression vector (Invitrogen) by PCR-amplification of p23. The strep-tag (WSHPQFEK) was either N-or C-terminally attached to p23. The mutants (D142A, D145A and the double mutant D142/145A) were generated by overlapping PCR primer extension. To generate deletion p23 cleavage in leukemic apoptosis G Gausdal et al mutants of p23, the regions encoding residues 1-141, residues 1-142 and residues 1-145 were amplified by PCR and subcloned into pcDNA5/FRT with a C-terminal strep-tag. All the constructs were verified by enzyme digestion and DNA sequencing.
In vitro 35 S-p23 cleavage assay
35
S-p23 was produced by in vitro transcription and translation using the TNT T7 coupled Reticulocyte Lysate System (Promega, Madison, WI, USA). Rabbit reticulocyte lysate was combined with 2 mg of plasmid (wild type, mutated or truncated forms of p23 cDNA) in the presence of 35 S-methionine and T7 RNA polymerase, and the reactions were incubated for 90 min at 301C. For in vitro cleavage reactions, 1 U of recombinant caspase was added to 1-3 ml of reaction mixture containing in vitro translated 35 S-p23 in a total volume of 20 ml 20 mM HepesNaOH, pH 7.4, 50 mM NaCl, 1 mM EDTA, 10 mM DTT, 1% sucrose and 0.1% CHAPS and incubated for 3 h at 371C. The reactions were stopped by addition of SDS-sample buffer and boiling for 5 min. For cleavage reactions with GA, GA was incubated with 35 S-p23 for 3 h prior to the addition of recombinant caspase. The cleavage reactions were separated on SDS-PAGE (4% stacking gel and 15% separation gel), and the gels were dried and subjected to phosphoimaging analysis on a Fuji BAS5000.
Results
Hsp90 co-chaperone p23 is subject to limited proteolysis in drug-induced AML cell apoptosis
In a search for novel protein targets in anthracycline-induced apoptosis, we subjected HL-60 cells treated with DNR to 2DE and searched the gels for changes in the protein pattern. One protein with isoelectric point (pI) 3.7 and molecular weight (Mw) 20 kDa was found to disappear upon treatment with DNR (Figure 1a-c) . Analysis by MALDI-TOF-MS revealed this protein to be Hsp90 co-chaperone p23. The MS data covered 52.5% of the sequence.
While the calculated size of p23 (18.7 kDa) fits well with the observed size, the calculated pI (4.35) was higher than the observed pI of 3.7. This discrepancy prompted us to confirm the MS identification of p23 by pull down of p23 with anti-p23 antibody. For this, 35 S-methionine labeled HL-60 cells was treated with DNR and cell extracts were immunoprecipitated with p23 and analyzed by 2DE. In vehicle-treated cells, a protein with pI and Mw in the expected range (pI B3.5, Mw B20 kDa) was indeed pulled down with anti-p23 (Figure 1d) . A smaller and slightly more basic protein (pI B4.1, Mw B17 kDa) was pulled down in DNR-treated cells (Figure 1e ) indicating that treatment with DNR induced a limited degradation of p23 into a stable 17 kDa fragment. To further ensure the identity of the spot as co-chaperone p23, the anti-p23 immunoprecipitate was analyzed by Western blotting with anti-Hsp90, a well-known partner protein for p23. Hsp90 coimmunoprecipitated with p23 both in Ctrl cells and in apoptotic DNR-treated cells (Figure 1f) . We conclude therefore that co-chaperone p23 is subjected to limited degradation in DNR-treated HL-60 cells, and that both the native and the proteolysed form of p23 can bind Hsp90. The discrepancy between the observed and calculated pI suggests that p23 is subject to acidifying modifications like phosphorylations in the intact cell. In line with this, it has recently been reported that p23 is a substrate of casein kinase II. 23 The degree of post-translational modifications can be heterogeneous since p23 appeared as a series of closely spaced subspots both before and after DNR treatment (Figure 1d,e) .
In order to know if p23 was targeted in DNR-induced death also in other leukemic cell lines, we studied the NB4 cell line, which unlike HL-60 cells have retained the characteristic t(15;17) abnormality of promyelocytic leukemia. 24 We found a similar size-shift in p23 from 20 to 17 kDa in NB4 cells treated with DNR (Figure 2a ). The degradation of p23 was not unique for cells treated with DNR and could also be induced by other commonly used antileukemic drugs like IDA, cytarabine or etoposide (Figure 2a ). An intriguing observation was that the rate of p23 degradation only increased as a function of drug concentration at low and moderate drug levels. No further enhancement of p23 degradation was observed at higher concentrations. This indicated that p23 was targeted at therapeutically relevant concentrations of the drugs and that the relevant drug target displayed saturation kinetics arguing against the drug effects being non-specific.
To see if p23 proteolysis was limited to leukemic cell lines, we treated the mammary carcinoma cell line MCF-7 with DNR and DOXO, an anthracycline used in the therapy of solid tumors (Figure 2b) . At apoptotic levels comparable to those in the leukemic cell lines, the proportion of p23 being cleaved appeared less in the MCF-7 cells, but also in this cell line p23 was converted to a 17 kDa fragment as a result of drug treatment. We conclude that p23 is subject to proteolysis in several cell types in response to a number of chemotherapeutic drugs. p23 cleavage in leukemic apoptosis G Gausdal et al p23 is subject to cleavage by both caspase-3 and -7
Anthracyclines are known to induce the activation of caspases. 4 Initiator caspases like caspase-2, -8 and -9 activate effector caspase-3 and -7 as well as other caspases. 25 Hence, in the early stages of apoptosis, a broad spectrum of caspases would be expected to be active. To know if any of these could be responsible for the observed change in p23 size, we induced apoptosis in the presence of the broad range caspase inhibitor zVAD. When apoptosis was induced in the presence of a high concentration of zVAD, there was no cleavage of p23, and the cleavage of procaspase-3 was strongly decreased (Figure 3a) . This indicated that p23 was targeted by caspase(s). When apoptosis was induced in the presence of the caspase-3/-7 inhibitor DEVD we observed inhibition of p23 cleavage (Figure 3b ), indicating that p23 is cleaved mainly, if not uniquely, by caspase-3 and/or -7. Procaspase-3 and PARP were still cleaved in the presence of DEVD (Figure 3b ). This was expected since procaspase-3 is cleaved by the upstream caspase-8 and -9, and there is a redundancy for caspases cleaving PARP. [26] [27] [28] We conclude from the caspase inhibition studies that p23 most probably is cleaved by caspase-7 and/or -3 in cells induced to undergo apoptosis.
In order for caspase-3 or -7 to be able to cleave p23, they should at least be partially activated at the stage of apoptosis when p23 cleavage is initiated. In Western blots of HL-60 cells treated with DNR for various periods of time, the lower Mw species (17 kDa) of p23 was noticed after about 3 h, and after 8 h all p23 immunoreactivity had become converted from the 20 kDa to the 17 kDa band (Figure 3c ). The earliest signs of p23 band-shift occurred about the same time as the cleavage of procaspase-3 and -7, but once started, the cleavage of the procaspases proceeded more rapidly (Figure 3c ). We conclude that both caspase-3 and -7 are activated early enough in druginduced apoptosis to be able to cleave p23. The fact that MCF-7 cells, which lack caspase-3, 29 still showed p23 cleavage (Figure 2b) suggests that caspase-7 can cleave p23 on its own, but does not exclude a role for caspase-3.
In order to know if p23 was subject to cleavage by caspase-7 alone or if p23 could be a target of both caspase-3 and -7, we studied the cleavage of in vitro translated 35 S-p23 by recombinant caspase-7 and -3 ( Figure 4b , left subpanel). We found that both caspases were able to convert untagged and C-terminally strep-tagged wild-type p23 to a fragment of the same size (17 kDa) as observed in cellular apoptosis. We conclude therefore that both caspase-7 and -3 are capable of cleaving p23. Caspases recognize specific target sequences and cleave at the C-terminal end of aspartic acid residues. Caspase-3-like enzymes recognize preferentially the DXXD recognition motif. 30 The amino-acid sequence of p23 contains nine potential target sites (Figure 4a ). Cleavage at D63, D111, or D114 was unlikely because the resulting cleavage products would have size less than 14 kDa. Cleavage at D13 was improbable because it would produce a fragment with a predicted lower pI than uncleaved p23, rather than the observed higher pI for cleaved p23 (Figure 2e) . In order to know if D26 was an actual cleavage site, we compared the fragment sizes produced by caspase-7 between wild-type p23 with no tag (Figure 4b upper band of doublets in upper subpanel). We noted that a 17 kDa fragment was produced after cleavage of p23 with no tag and C-terminal tag, but that a 17/18 kDa doublet was produced when a mixture of untagged and N-terminally tagged p23 was cleaved. We conclude therefore that the cleavage must remove about 3 kDa from the C-terminal end of p23, thus excluding D26 as a relevant caspase cleavage site. Previous mutagenesis studies on recombinant p23 suggesting that the C-terminal tail of p23 is not essential for Hsp90 interaction 21 and our finding that cleaved p23 still binds to Hsp90 (Figure 1 ) supports this conclusion. Further, this conclusion was corroborated by the finding that p23(1-141)-strep and p23(1-142)-strep were not cleaved (Figure 4b) .
In order to know which of D142, D145, D150, or D153 was the relevant cleavage site(s), we studied the cleavage of p23(1-145)-strep (Figure 4b ). This protein was cleaved to a 17 kDa fragment suggesting that either D142, D145 or both were the relevant cleavage sites. This conclusion was supported by the fact that the double mutant p23D142A/D145A failed to be cleaved (Figure 4c lower subpanel) . Since the single mutations p23D142A and p23D145A were both cleaved (Figure 4c) , we conclude that p23 has two relevant cleavage sites in its Cterminal tail. It was intriguing that not only p23(1-141)-strep, but also p23(1-142)-strep was protected against cleavage, since p23(1-142)-strep contains an intact D142. This suggests that the residues C-terminal of D142 in p23 (GAD) may facilitate cleavage better than the residues introduced by the strep-tag (WSH).
Hsp90 inhibitor geldanamycin enhances cleavage of p23 in vitro and in vivo p23 is believed to be part of the Hsp90 multiprotein-complex. 10 GA binds to the nucleotide pocket of Hsp90 and brings the Hsp90 dimer into a conformation not recognized by p23. 12 Hence, when GA is present, p23 is liberated from Hsp90. To know whether binding of p23 to Hsp90 could protect p23 towards caspase cleavage, GA was added to the reticulocyte lysate containing 35 S-p23 prior to cleavage with recombinant caspase-7. Since the reticulocyte lysate has a high concentration of both heat-shock chaperones and ATP, we expected that a high concentration of GA would be required to effectively compete with the ATP bound to Hsp90 in the lysate. We found that GA concentrations at 50 mM and higher did enhance the cleavage of p23 by caspase-7 ( Figure 5a) .
Next, we wanted to know if GA could enhance p23 cleavage also in intact HL-60 cells treated with anthracyclines (Figure 5b) . After 4 h of treatment with DNR, there was more cleaved p23 when GA was present compared to treatment with DNR alone. At 8 h, the cleavage of p23 was more complete when cells were coincubated with the two drugs. Similar results were observed in cells treated with IDA (data not shown). GA treatment itself did not induce p23 cleavage. This indicates that the cleavage of p23, both non-Hsp90 associated and Hsp90 associated, was dependent on active caspases.
We then wanted to investigate whether the increased cleavage of p23 observed in the presence of GA could also be explained by enhanced caspase activation. We noted stronger cleavage of procaspase-3 and -7 in cells treated with anthracyclines in the presence of GA (Figure 5b ). This suggests that the increased p23 cleavage induced by GA may be due both to increased caspase activity and to dissociation of the p23/Hsp90 complex.
Hsp90 inhibitor geldanamycin enhances anthracycline-induced apoptosis
Having demonstrated that GA enhanced caspase activation and p23 cleavage, a final question was whether GA also had an enhancing effect on anthracycline-induced apoptosis. This was found to be the case (Figure 6 ). DNR and IDA induced apoptosis earlier when GA was present. The apoptosis-enhancing effect of GA was highest when GA was added prior to the anthracycline. The difference in apoptosis between cells treated in the absence and presence of GA was highly significant (P ¼ 0.006 for GA þ DNR vs DNR and P ¼ 0.005 for GA þ IDA vs IDA). No morphological signs of apoptosis (data not shown) or caspase activation ( Figure 5b) were detected in cells treated with GA only.
Discussion
Members of the Hsp family show an increased expression in stressed cells and protect cells from lethal malfunction by providing stabilization of survival-promoting proteins and by inhibiting apoptosis-inducing factor (AIF) and caspases. 31, 32 In leukemias, as well as other malignancies, an elevated expression of Hsp90 has been demonstrated in cells freshly isolated from patients. 33 We report here that the Hsp90 co-chaperone p23 is a caspase target in chemotherapy-induced apoptosis in AML. The cleavage is redundant both in the sense that two adjacent cleavage sites exist (D142 and D145) and that both caspase-7 and -3 are able to cleave p23. The 17 kDa product was stable in the apoptotic cells, introducing the possibility that it could have a novel function of its own. This possibility is actively investigated in our laboratory. Although any novel function of the p23 cleavage is unknown, there is reason to believe that the cleavage leads to compromised chaperone activity of p23. The p23 co-chaperone appears to enhance the assembly of Hsp90 and client proteins as well as be a part of the ATP-driven peptide-release cycle. 34 Oxelmark and colleagues established that the whole C-terminus of p23 was required for full activity with respect to estrogen receptor signal transduction in yeast. 35 Weikl and colleagues 21 reported that removal of the C-terminal 30 amino-acid residues of p23 compromised its chaperone activity. The apotosis-associated cleavage of p23 will therefore most likely affect p23's chaperone activity in the Hsp90-complex and destabilize Hsp90 interactions with client proteins resulting in a reduction of survival signaling. We believe therefore that cleavage of p23 can enhance cell death. In line with this, factors enhancing cleavage of p23, like GA, enhanced the apoptotic cell death (Figures 5 and 6 ).
p23 has been reported to be identical to cytosolic prostaglandin E 2 synthase (cPGES), 36 whose activity depends on binding to Hsp90. 37 Whether the cPGES activity of p23 is affected by the caspase-mediated cleavage is not known, but this is an interesting possibility in view of the ability of PGE 2 to stimulate adenylyl cyclase and the production of cAMP, which can modulate apoptosis in hematologic cells. 38, 39 Caspase-3 has been considered the major executioner caspase, the function of caspase-7 being considered to be modest. 28 There is, however, emerging evidence that caspase-7 Geldanamycin enhanced the rate of anthracyclineinduced apoptosis. Apoptosis was induced in HL-60 cells with 1.6 mM DNR or 0.4 mM IDA, and 0.1 mM GA was added either at the same time or 2 h prior (t ¼ À2) to the addition of DNR or IDA. At indicated times, cells were fixed and scored for apoptosis. Induction of apoptosis was higher for cells treated with DNR and GA compared to just DNR (P ¼ 0.006) or with IDA and GA compared to just DNR (P ¼ 0.005). For further details, see Materials and methods.
p23 cleavage in leukemic apoptosis G Gausdal et al can be involved during the early stages of etoposide-and staurosporine-induced apoptosis. 40 To the best of our knowledge, the p23 cleavage sites PEVD 142 GAD 145 have not been reported before, but we note that the pSET protein, which is upregulated in some cases of AML, is cleaved at a site (SNHDGAD) 41 with the same C-terminal amino-acid sequence (GAD) as the D142 of p23. We noted that replacement of the native GAD sequence by the WSH sequence of the strep-tag abolished caspase cleavage at D142 (Figure 4b ), suggesting that a C-terminal GAD sequence could in fact enhance cleavage at this site. The cleavage of p23 occurred in both MCF-7 mammary carcinoma cells and in HL-60 and NB4 leukemia cells, and in response to a variety of chemotherapeutic drugs. These facts, and the susceptibility of p23 to cleavage by both caspase-3 and -7, suggest that p23 may be a general target in apoptotic cell death. In fact, p23 has recently been found to be cleaved following CD95/Fas cross-linking in Jurkat cells. 20, 42 GA induces ubiquitinylation and proteasomal degradation of Hsp90 client proteins such as survival-promoting protein kinases and transcription factors. 16, 17 In HL-60 cells, 17-AAG has been shown to attenuate intracellular levels of a number of Hsp90 client proteins such as Akt, c-Raf and c-Src, and induce expression of the proapoptotic proteins Bax and Bak as well as apoptosis. 43 In our experiments with shorter GA incubation times (6-8 h as compared to 16-48 h 43 ), GA did not cause induction of apoptosis on its own. However, HL-60 cells treated with both anthracyclines and GA showed a significant increase in cell death with earlier cleavage of procaspase-7 and -3 and p23. We were also able to increase p23 cleavage in vitro, but only at high (50 mM) GA concentrations. This is much more than what is believed to be required to disrupt the Hsp90 multiprotein complex in intact cells. 44 The reason for this discrepancy could be dual. First, the rabbit reticulocyte lysate contains large amounts of chaperones like Hsp90. 45, 46 Therefore, the GA must inactivate a high percentage of Hsp90 to abolish its binding capacity for the pool of 35 S-p23 present. Second, Hsp90 from tumor cells are thought to have an increased affinity for 17-AAG compared to Hsp90 from normal cells. 7 The C-terminal tail of p23 appears to be crucial for its chaperone activity 21 and p23 has been postulated to have chaperone activity also in the absence of Hsp90. 13, 14 Therefore, one would expect that the combination of GA and p23 cleavage would lead both to p23 dissociation from Hsp90 and suppression of any endogenous chaperone activity. This could be particularly important in leukemias dependent on Hsp90-associated protein kinases as Bcr-Abl or mutated Flt3 for survival. Such cells are particularly resistant to conventional chemotherapy, but are also particularly sensitive to drugs targeting Hsp90. 47, 48 In conclusion, we have shown that conventional chemotherapeutic agents target Hsp90 through caspase-dependent cleavage of Hsp90 co-chaperone p23. This contributes to our understanding of how these successful drugs work. We have also shown that the Hsp90 inhibitor GA leads to a more rapid cleavage of p23 than what is possible with conventional chemotherapeutic drugs alone. This may explain why Hsp90 inhibitors are particularly efficient against cells overexpressing constitutively active Hsp90 client proteins, and suggests that further studies are warranted to (1) elucidate the exact role of native and truncated p23 in cancer cell survival, (2) design drugs directed against co-chaperone p23, and (3) improve further on combinational therapy using conventional chemotherapeutic drugs and presently available Hsp90 inhibiting drugs.
